# INTRAFAMILIAL TRANSMISSION OF HEPATITIS C

Thesis submitted in Partial Fulfillment for the Master Degree in Internal Medicine

By in.

. . . 42

Esam Abd El-Monem Abd El-Maksod

616.3623 (M.B.B.Ch.)

Supervised By

Prof. Dr. Mohamed Abd El-Fattah Taha

Prof. of Internal Medicine Faculty of Medicine, Ain Shams University

Prof. Dr. Abd El-Ghany Shawkat Mohamed

Prof. of Internal Medicine Faculty of Medicine, Ain Shams University

Dr. Maha Ali Ezz El-Din

M.D. Clinical Pathology

1997





## قالوا سبحانك لا علم لنا الا ما علمتنا انك انت العليم الحكيم



### Acknowledgment

First and foremost I feel always indebted to GOD, the most kind and the most mericful

I would like to express my deepest gratitude and appreciation to Prof. Dr. Mohamed Abd El-Fattah Taha, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for the great help he offered, the fruitful advices and encouragement throughout the whole work.

Special thanks are due to Prof. Dr. Abd El-Ghany Shawkat Mohamed, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for dedicating so much of his precious time and effort, and for his kindness, constant guidance to complete this work.

Thanks are also due to Dr. Maha Ali Ezz El-Din, M.D. Clinical Pathology, Specialist in Clinical Pathology, Ain Shams Hospital, for her assistance and help throughout this work.



#### CONTENTS

INTRODUCTION	1
AIM OF THE WORK	2
REVIEW OF LITERATURE Virology Epidemiology Clinical presentation and Sequelae Pathogenesis and Histopathology Diagnosis Prevention Treatment Familial risk in common diseases	3 3 9 22 28 30 36 38 41
SUBJECTS AND METHODS	46
RESULTS	51
DISCUSSION	78
SUMMARY	90
RECOMMENDATION	94
REFERENCE	95
AR ARIC SIMMARY	

#### LIST OF TABLES

#### Tables in Review

Table (1):	Milestones in the history of non-A, non-B hepatitis "hepatitis C".	3
Table (2):	Perinatal transmission of HCV	18
Table (3):	Population and recurrence risks for NIDDM and IDDM	43
Table (4):	Recurrence risks for hypertension.	44
Tables in I	Results	
Table. (1):	Prevalence of anti HCV among family contacts to index and control cases	65
Table (2):	Comparison between the mean age of index and control cases.	65
Table (3):	Comparison between the mean age of anti HCV negative and positive contacts to index cases	65
Table (4):	Comparison between the mean age of anti HCV negative and positive contacts to control cases	66
Table (5):	Sex distribution among index and control cases	66
Table (6):	Sex distribution among contacts to index cases and its relation to anti-HCV.	66
Table (7):	Sex distribution among contacts to control cases and its relation to anti -HCV	67
Table (8):	Prevalence of anti-HCV among contacts according to	67

Table (9):	their relation to control cases.	67
Table (10):	Comparison between anti-HCV positive and negative spouses of index cases according to duration of marriage.	68
Table (11):	Comparison between anti-HCV positive and negative spouses of control cases according to duration of marriage.	68
Table (12):	Prevalence of risky occupation among index and control cases	68
Table (13):	Prevalence of risky occupation among contacts to index cases and its relation to anti-HCV	69
Table (14):	Prevalence of risky occupation among contacts to control cases and its relation to anti-HCV	69
Table (15):	Incidence of Blood transfusion among index and control cases.	69
Table (16):	Incidence of Blood transfusion among contacts to index cases and its relation to anti-HCV.	70
Table (17):	Incidence of Blood transfusion among contacts to control cases and its relation to anti-HCV	70
Table (18):	Incidence of surgical operations among index and control cases.	70
Table (19):	Incidence of surgical operations among contacts to index cases and its relation to anti-HCV	71
Table (20):	Incidence of surgical operations among contacts to control cases an its relation to anti-HCV	71
	Incidence of injections with non disposable syringes	71

Table (22):	Incidence of injections with non disposable syringes among contacts to index cases and its relation to anti-HCV	72
Table (23):	Incidence of injections with non disposable syringes among contacts to control cases and its relation to anti-HCV.	72
Table (24):	Incidence of frequent dentist visits among index and control cases.	72
Table (25):	Incidence of frequent dentist visits among contacts to index cases and its relation to anti-HCV.	73
Table (26):	Incidence of frequent dentist visits among contacts to control cases and its relation to anti-HCV	73
Table (27):	Incidence of exposure to identifiable risk factor among anti HCV positive contacts to index cases.	73
Table (28):	Comparison between index and control cases according to the locality	74
Table (29):	Comparison between anti HCV positive and negative contacts to index cases according to their locality	74
Table (30):	Comparison between anti HCV positive and negative contacts to control cases according to their locality	74
Table (31):	Comparison between index and control cases according to the stander of life	75
Table (32):	Comparison between anti HCV positive and negative contacts to index cases according to their stander of life	75
Table (33):	Comparison between anti HCV positive and negative contacts to control cases according to their stander of	75

Table (34):	Comparison between anti HCV positive and negative contacts to index cases and its relation to the use of	
	common nail scissors	76
Table (35):	Comparison between anti HCV positive and negative contacts to control cases and its relation to the use of common nail scissors	76
Table (36):	Comparison between anti HCV positive and negative contacts to index cases and its relation to the use of common shaving blades.	76
Table (37):	Comparison between anti HCV positive and negative contacts to control cases and its relation to the use of common shaving blades	77

## LIST OF FIGURES

Fig. (1):	Schematic organization of HCV genome	5
	Epidemiologic risk factors among patients with acute and chromic HCV infection in USA	
Fig. (3):	Serologic course of (A) acute HCV infection and (B) chronic HCV infection HCV RNA was detected by the PCR EIA-1 = first-generation enzyme-linked immunosorbent assay for antibody to HCV (c100-3 antigen); EIA-2 = second-generation enzyme-linked immunosorbent assay for antibody to HCV (c200 and	
Fig. (4):	Human disease as being represented on a spectrum	35
	ranging from those which are largely environmental to those which are entirely genetic.	41

